Drug importation could shape medical marketing
The FDA’s approval of Florida’s plan to import drugs is official. Healthcare marketers will have to develop communication around the law’s process and impact to patients and stakeholders.
The FDA’s approval of Florida’s plan to import drugs is official. Healthcare marketers will have to develop communication around the law’s process and impact to patients and stakeholders.
It was a long time coming but the Food and Drug Administration greenlit Florida’s plan to import lower cost drugs from Canada.
The agency’s historic move toward drug pricing reform last week allows the Sunshine State to become the first state to buy drugs in bulk for its Medicaid program from Canada.
It’s estimated the action may save up to $150 million just in the first year of the initiative. Since Canada, like many other countries, can negotiate directly with drugmakers to set a lower cost for medications — prescription drugs are cheaper there as a whole than they are in the U.S.
Leslie Isenegger, who leads Real Chemistry’s corporate pricing and public affairs practice, says the decision is a significant one because people have been talking about drug reimportation for more than 20 years and it finally came to pass.
In the early 2000s, Congress passed a law that allowed drug importation under strictly defined circumstances — only if the Department of Health and Human Services (HHS) Secretary deemed importation safe for the American public, and if it would result in cost savings for patients.
However, the law was never implemented, largely due to pushback from industry groups, who argued that drug importation would raise safety issues.
“The fact that the FDA has given a nod to this, just in and of itself, is unprecedented,” Isenegger says.
Unsurprisingly, the pharma industry immediately expressed opposition to the FDA’s approval last week, with lobbying group PhRMA noting in a statement that the decision was “reckless” and that “the importation of unapproved medicines, whether from Canada or elsewhere in the world, poses a serious danger to public health.”
Hoe de mislukte datagedreven droom van marketing te herstellen Marketeers is een droom verkocht: verzamel meer data en je krijgt betere inzichten om slimmere beslissingen te nemen. We hebben allemaal big data nagejaagd...
Is jouw Google Ads-strategie futureproof? Doe een SEA check! Zijn Google Ads nog relevant in 2025? Google Ads stond jarenlang centraal in digitale marketingstrategieën. Maar met de opkomst van bijvoorbeeld Social Search...
10 effectieve beïnvloedingstechnieken Beïnvloedingstechnieken spelen een belangrijke rol in marketing en psychologie. Hoewel Robert Cialdini met zijn 7 principes – wederkerigheid, schaarste, autoriteit, consistentie...
Pharmamarketeer richt zich op marketingprofessionals van farmaceuten en andere medisch-gerelateerde organisaties in Nederland en België.
Copyright 2023 © Uitgave van MedHealth Communications BV | Privacy disclaimer